Enorama Pharma AB (publ) (ERMA.ST)
SEK 2.95
(3.15%)
SEK 2.95
(3.15%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -41.83 Million SEK | -0.89% |
| 2022 | -41.47 Million SEK | -53.93% |
| 2021 | -26.94 Million SEK | -17.07% |
| 2020 | -23.01 Million SEK | -0.59% |
| 2019 | -22.87 Million SEK | -47.66% |
| 2018 | -15.49 Million SEK | -95.98% |
| 2017 | -7.9 Million SEK | -3.03% |
| 2016 | -7.67 Million SEK | -1272.56% |
| 2015 | -559 Thousand SEK | -1652.78% |
| 2014 | 36 Thousand SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -6.34 Million SEK | 36.79% |
| 2024 Q1 | -10.03 Million SEK | 10.79% |
| 2023 Q1 | -9.75 Million SEK | 27.03% |
| 2023 Q3 | -12.51 Million SEK | -43.89% |
| 2023 Q2 | -8.69 Million SEK | 10.86% |
| 2023 FY | -41.83 Million SEK | -0.89% |
| 2023 Q4 | -11.24 Million SEK | 10.14% |
| 2022 Q3 | -7.07 Million SEK | 32.11% |
| 2022 Q4 | -13.36 Million SEK | -88.92% |
| 2022 FY | -41.47 Million SEK | -53.93% |
| 2022 Q1 | -10.86 Million SEK | -44.6% |
| 2022 Q2 | -10.42 Million SEK | 4.09% |
| 2021 Q3 | -8.17 Million SEK | -52.64% |
| 2021 FY | -26.94 Million SEK | -17.07% |
| 2021 Q4 | -7.51 Million SEK | 8.02% |
| 2021 Q1 | -5.89 Million SEK | 51.0% |
| 2021 Q2 | -5.35 Million SEK | 9.16% |
| 2020 FY | -23.01 Million SEK | -0.59% |
| 2020 Q2 | -1.77 Million SEK | 59.73% |
| 2020 Q1 | -4.41 Million SEK | 37.4% |
| 2020 Q3 | -4.78 Million SEK | -169.35% |
| 2020 Q4 | -12.02 Million SEK | -151.14% |
| 2019 Q3 | -7.49 Million SEK | -89.75% |
| 2019 Q4 | -7.05 Million SEK | 5.95% |
| 2019 FY | -22.87 Million SEK | -47.66% |
| 2019 Q1 | -4.36 Million SEK | 27.95% |
| 2019 Q2 | -3.95 Million SEK | 9.48% |
| 2018 Q2 | -3.1 Million SEK | -4.12% |
| 2018 FY | -15.49 Million SEK | -95.98% |
| 2018 Q4 | -6.05 Million SEK | -81.1% |
| 2018 Q3 | -3.34 Million SEK | -7.76% |
| 2018 Q1 | -2.98 Million SEK | -22.71% |
| 2017 Q3 | -2.11 Million SEK | -16.37% |
| 2017 Q1 | -1.53 Million SEK | 17.52% |
| 2017 Q2 | -1.82 Million SEK | -18.41% |
| 2017 FY | -7.9 Million SEK | -3.03% |
| 2017 Q4 | -2.43 Million SEK | -14.74% |
| 2016 Q1 | -2.69 Million SEK | -466.21% |
| 2016 FY | -7.67 Million SEK | -1272.56% |
| 2016 Q4 | -1.86 Million SEK | -77.82% |
| 2016 Q3 | -1.04 Million SEK | 69.82% |
| 2016 Q2 | -3.47 Million SEK | -28.64% |
| 2015 FY | -559 Thousand SEK | -1652.78% |
| 2015 Q2 | -381 Thousand SEK | 37.95% |
| 2015 Q3 | -302 Thousand SEK | 20.73% |
| 2015 Q4 | 737 Thousand SEK | 344.04% |
| 2015 Q1 | -614 Thousand SEK | 0.0% |
| 2014 FY | 36 Thousand SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AcuCort AB | -13.24 Million SEK | -215.782% |
| AlzeCure Pharma AB (publ) | -38.26 Million SEK | -9.346% |
| BioGaia AB (publ) | 440.9 Million SEK | 109.489% |
| Enzymatica AB (publ) | -48.06 Million SEK | 12.95% |
| Gabather AB (publ) | -9.47 Million SEK | -341.609% |
| Klaria Pharma Holding AB (publ.) | -14.68 Million SEK | -185.0% |
| Moberg Pharma AB (publ) | -27.46 Million SEK | -52.343% |
| Nanexa AB (publ) | -76.62 Million SEK | 45.399% |
| Newbury Pharmaceuticals AB (publ) | -14.07 Million SEK | -197.187% |
| ODI Pharma AB | -1.34 Million SEK | -3018.422% |
| Orexo AB (publ) | -109.5 Million SEK | 61.792% |
| Probi AB (publ) | 11.32 Million SEK | 469.594% |
| Swedencare AB (publ) | 173.2 Million SEK | 124.156% |
| Swedish Orphan Biovitrum AB (publ) | 4.65 Billion SEK | 100.899% |
| Toleranzia AB | -7.89 Million SEK | -430.199% |
| Vivesto AB | -356.71 Million SEK | 88.271% |